Ipca Labs in alliance with Ranbaxy for US market

New Delhi, Sep 21 (UNI) Drug maker Ipca Laboratories Ltd today entered into an alliance with Ranbaxy Pharmaceuticals Inc to market its products in the US and said it is setting up a new formulations manufacturing facility at SEZ, Indore, at an initial investment of Rs 60 crore.

''Under this alliance, Ipca Labs will develop a number of generic prescription pharmaceutical products which will be marketed by Ranbaxy in the US,'' a company statement said.

Ranbaxy will file for regulatory approval and initially support manufacturing of these products. The first product to be launched under the alliance will be Furosemide Tablets 20mg, 40mg, and 80mg which have recently received the US FDA approval.

Ipca Labs stated it is setting up a manufacturing facility, meeting US regulatory requirements, at SEZ Indore with an initial capital outlay of Rs 60 crore. In the future, the company will manufacture such products utilising its facilities in India.

Most of these products will be supported using its DMF approved Active Pharmaceutical Ingredients (APIs).

Ranbaxy Pharmaceuticals Inc, a wholly-owned subsidiary of domestic drug major Ranbaxy Laboratories Ltd, will commercialise these products in the US market utilising its established marketing expertise and distribution network.

Ranbaxy Pharmaceuticals Inc is engaged in the sale and distribution of generic and branded prescription products in the US healthcare system.

UNI SRS PV DS1240